---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002591"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:06:06.700687+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M

## Summary
- Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.
- GAAP net loss $4.7M ($0.11 loss per share) vs net income $0.6M ($0.01 EPS) a year ago.
- Adjusted operating income $1.2M, down from $4.4M; adjusted EBITDA $1.6M, down from $4.8M.
- CEO cites APAC market headwinds and strong prior-year comp; cost reduction initiative announced post-quarter.
- Expects solid growth in second half aided by new product launches and Chinese stimulus.

## SEC filing metadata
- accession: 0001171843-24-002591
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/0001171843-24-002591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/f8k_050724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002591
- JSON: https://secwatch.observer/filing/0001171843-24-002591.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002591.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2024 results: revenue $24.5, net income $(4.7), EPS $(0.11) per diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $24.5
  - Net income: $(4.7)
  - EPS: $(0.11) per diluted share
  - Result: reported results
  source text: continue to expect solid growth in the second half.” Financial Results Summary Three Months Ended March 31, (unaudited, $ in millions except per share data) 2024 2023 Revenues $ 24.5 $ 30.0 Gross margin 60.3 % 61.2 % Operating (loss) income (GAAP) $ (2.3 ) $ 1.7 Adjusted operating income $ 1.2 $ 4.4 Net (loss) income (GAAP) $ (4.7 ) $ 0.6 Diluted (loss)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/0001171843-24-002591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.